Gilead Boosts Sales Forecast on Demand for Covid-19 Drug

Gilead Sciences headquarters in Foster City, California.

Photographer: David Paul Morris/Bloomberg
Lock
This article is for subscribers only.

Gilead Sciences Inc. raised its sales forecast for the year, mostly due to anticipated demand for the Covid treatment Veklury.